Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Brooke M. Rock"'
Autor:
Babak Basiri, Fang Xie, Bin Wu, Sara C. Humphreys, Julie M. Lade, Mai B. Thayer, Pam Yamaguchi, Monica Florio, Brooke M. Rock
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss , Pp 725-736 (2020)
There has been a renewed interest in therapeutic small interfering RNAs (siRNAs) over the past few years. This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver. In genera
Externí odkaz:
https://doaj.org/article/31612adf3dbc4f6d9346df118252c413
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Abstract Oligonucleotide therapeutics use short interfering RNA (siRNA) or antisense oligonucleotide (ASO) molecules to exploit endogenous systems—neutralizing target RNA to prevent subsequent protein translation. While the potential clinical appli
Externí odkaz:
https://doaj.org/article/22cff2a3388640828a7f309b40b4cccd
Autor:
William C. Fanslow, Kim C. Quon, Matthew M. Bio, Margaret F. Weidner, Wesley S. Chang, Jason W. O'Neill, Christopher J. Borths, Dan A. Rock, Seamus P. Ragan, Sophia Siu, Robert R. Milburn, Sonal K. Patel, Brooke M. Rock, Mark E. Tometsko, Jesse L. Gurgel, Allison P. Jacob, Kevin J. Hamblett
Genes identified as critical for CD70 ADC function in Library 1 screen (S1); Genes identified as critical for CD70 ADC function in Library 2 screen (S2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3afd7b980e59ed2ae74732dbadbd5224
https://doi.org/10.1158/0008-5472.22406852
https://doi.org/10.1158/0008-5472.22406852
Autor:
William C. Fanslow, Kim C. Quon, Matthew M. Bio, Margaret F. Weidner, Wesley S. Chang, Jason W. O'Neill, Christopher J. Borths, Dan A. Rock, Seamus P. Ragan, Sophia Siu, Robert R. Milburn, Sonal K. Patel, Brooke M. Rock, Mark E. Tometsko, Jesse L. Gurgel, Allison P. Jacob, Kevin J. Hamblett
Predicted topology for SLC46A3 (S1); Effect of siRNA on mRNA expression of SLC46A3 and CD70 in 786-0 cells (S2); Effect of siRNA on CD70 protein expression in 786-0 cells (S3); Anti-CD70 Ab-DSG-Maytansine and anti-CD70 Ab-Cys-Maytansine are potent ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eff3eb212c549f79dc7834903550168
https://doi.org/10.1158/0008-5472.22406858.v1
https://doi.org/10.1158/0008-5472.22406858.v1
Autor:
William C. Fanslow, Kim C. Quon, Matthew M. Bio, Margaret F. Weidner, Wesley S. Chang, Jason W. O'Neill, Christopher J. Borths, Dan A. Rock, Seamus P. Ragan, Sophia Siu, Robert R. Milburn, Sonal K. Patel, Brooke M. Rock, Mark E. Tometsko, Jesse L. Gurgel, Allison P. Jacob, Kevin J. Hamblett
Description of additional methods and procedures used in the study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33716785c78c5ac8ae1ee739e76fa395
https://doi.org/10.1158/0008-5472.22406855.v1
https://doi.org/10.1158/0008-5472.22406855.v1
Publikováno v:
Drug Metabolism and Disposition. 50:600-612
Autor:
Michael J. Koren, Patrick Maurice Moriarty, Seth J. Baum, Joel Neutel, Martha Hernandez-Illas, Howard S. Weintraub, Monica Florio, Helina Kassahun, Stacey Melquist, Tracy Varrieur, Saptarsi M. Haldar, Winnie Sohn, Huei Wang, Mary Elliott-Davey, Brooke M. Rock, Tao Pei, Oliver Homann, Jennifer Hellawell, Gerald F. Watts
Publikováno v:
Nature Medicine. 28:96-103
Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly targeting Lp(a) are currently available for clinical use. Here we report the discovery and development of olpasiran, a firs
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Scientific Reports
Oligonucleotide therapeutics use short interfering RNA (siRNA) or antisense oligonucleotide (ASO) molecules to exploit endogenous systems—neutralizing target RNA to prevent subsequent protein translation. While the potential clinical application is
Autor:
Mai B. Thayer, Brooke M. Rock, Jabbar Campbell, Sara C. Humphreys, Dan Adams, Wen Li Kelly Chen, Julie M. Lade
Publikováno v:
Journal of Medicinal Chemistry. 63:6407-6422
After two decades teetering at the intersection of laboratory tool and therapeutic reality, with two siRNA drugs now clinically approved, this modality has finally come into fruition. Consistent with other emerging modalities, initial proof-of-concep
Autor:
John T Barr, Henry J Wienkers, Brooke M. Rock, Zhican Wang, Dan A. Rock, Larry C. Wienkers, Xiaoshan Min
Publikováno v:
Drug Metabolism and Disposition. 48:508-514
Experiments designed to identify the mechanism of cytochrome P450 inactivation are critical to drug discovery. Small molecules irreversibly inhibit P450 enzymatic activity via two primary mechanisms: apoprotein adduct formation or heme modification.